Previous studies also show that both pharmacologic and genetic inhibition of MYD88 attenuate cardiac hypertrophy and apoptosis in myocardial infarction and pressure-overload mouse models in a TLR-NF-κb dependent manner [23], [40], [41]. This evidence concerns the gene NFKB1 and cardiac hypertrophy.